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Abstract

Periodontal diseases are among the most common diseases affecting humans. Dental biofilm is a
contributor to the etiology of most periodontal diseases. It is also widely accepted that immunological
and inflammatory responses to biofilm components are manifested by signs and symptoms of
periodontal disease. The outcome of such interaction is modulated by risk factors (modifiers), either
inherent (genetic) or acquired (environmental), significantly affecting the initiation and progression of
different periodontal disease phenotypes. While definitive genetic determinants responsible for either
susceptibility or resistance to periodontal disease have yet to be identified, many factors affecting the
pathogenesis have been described, including smoking, diabetes, obesity, medications, and nutrition.
Currently, periodontal diseases are classified based upon clinical disease traits using radiographs and
clinical examination. Advances in genomics, molecular biology, and personalized medicine may result in
new guidelines for unambiguous disease definition and diagnosis in the future. Recent studies have
implied relationships between periodontal diseases and systemic conditions. Answering critical
questions regarding host‐parasite interactions in periodontal diseases may provide new insight in the
pathogenesis of other biomedical disorders. Therapeutic efforts have focused on the microbial nature of
the infection, as active treatment centers on biofilm disruption by non‐surgical mechanical debridement
with antimicrobial and sometimes anti‐inflammatory adjuncts. The surgical treatment aims at gaining
access to periodontal lesions and correcting unfavorable gingival/osseous contours to achieve a
periodontal architecture that will provide for more effective oral hygiene and periodontal maintenance.
In addition, advances in tissue engineering have provided innovative means to regenerate/repair
periodontal defects, based upon principles of guided tissue regeneration and utilization of growth
factors/biologic mediators. To maintain periodontal stability, these treatments need to be
supplemented with long‐term maintenance (supportive periodontal therapy) programs.
Periodontology has been defined as ‘the scientific study of the periodontium in health and disease’ (6).
The periodontium includes the gingiva, alveolar bone, periodontal ligament and root cementum, i.e. the
tissues that support the teeth. The anatomy, histology and physiology of the normal periodontium have
been described in great detail elsewhere.347 They will not be covered in this context.
People exhibiting periodontal abnormalities, for example impairments of tissue integrity or function, are
said to have periodontal diseases. These comprise a variety of phenotypes; defined by clinical signs and
symptoms, they constitute the periodontal syndrome.44, 397, 404 The most frequently observed phenotype
is inflammation of the gingiva (gingivitis) induced by dental plaque (biofilm), and includes changes in
tissue color, volume, temperature, crevicular exudate and bleeding upon gentle provocation with a
probe.251 The clinical signs of biofilm‐associated gingivitis are reversible when adequate oral hygiene is
implemented and maintained.232 Less prevalent than gingivitis, but still observed in many persons, are
the clinical signs of biofilm‐associated periodontitis. They include periodontal pockets, attachment loss,
bleeding upon probing, and radiographic bone loss.117 Therapeutic efforts are directed towards
elimination of the suspected underlying infection, typically leading to resolution of the signs of
inflammation, tissue repair, and restoration of function and esthetics. The results of periodontal therapy
may be stable over a long time period, but signs of disease may return unpredictably in terms of
location, frequency and severity.

Many other phenotypes, frequently disease forms with severe signs and symptoms, have been
described and classified.145, 201 They are much less prevalent than typical biofilm‐associated gingivitis or
periodontitis. Some of the rare forms are related to systemic conditions; others are components of
genetic syndromes. Diagnostic criteria frequently used to characterize the various phenotypes of
periodontal syndrome are listed in Table 1.
Table 1. Diagnostic criteria used for periodontal diseases. A diagnosis can be made if two or more
diagnostic signs are present. The initial diagnosis is further characterized using two or more modifiers
Diagnostic signs and symptoms
Gingival color (or texture, volume or contour)
Gingival necrosis
Gingival enlargement
Gingival recession
Bleeding on provocation
Bleeding on probing
Pockets
Attachment loss
Bone loss
Tooth mobility
Lateral migration
Pain
Modifiers
Age of onset (early or adult)
Progression (chronic or rapid)
Response to treatment (stable or recurrent)
Severity (mild, moderate or severe)
Extent (localized or generalized)
The objective of this overview of principles of periodontology is presentation of current and established
concepts. Aspects of the history, classification, etiology, pathogenesis, epidemiology and treatment
modalities of the most common periodontal diseases are discussed.

History
Early Observations

Periodontal diseases, unlike caries, are not a by‐product of modern civilization. Manifesting themselves
as ante mortem loss of alveolar bone, signs indicative of periodontal pathology were discovered in
human specimens attributed to the Middle Pleistocene stage. For instance, indications of alveolar bone
resorption were found in the 640‐ to 735,000‐year‐old Mauer mandible (Homo heidelbergensis) in
Germany, and in a 169‐ to 191,000‐year‐old mandible that was unearthed at the Bau de l’Aubésier,
Vaucluse, France.91, 224 Such findings support the theory that periodontal diseases have plagued humans
and their phylogenetic ancestors for a very long time.
Chinese physicians were probably first to describe signs of periodontal diseases. Diagnoses and
treatments were presented in the earliest known textbook of Chinese medicine, Nei Ching, attributed to
Huang Di (approximately 2700–2600 BC).357 The ancient Egyptian Ebers Papyrus was written
approximately 1000 years later (approximately 1550 BC). It is one of the oldest fully preserved
medical documents, and contains several passages on remedies to cure conditions such as loose teeth
and swollen gums (‘flesh’).139 In Ancient India, Sushruta (approximately 6th century BC) illustrated a
large number of surgical instruments, and explained 300 surgical procedures in the treatise Samhita.
Sushruta taught a holistic approach to medical therapy. In pursuit of his philosophy, he described four
periodontal conditions, offering probably the first classification of periodontal diseases.357
In 1563, the Italian Renaissance anatomist and physician Bartolomeo Eustachi (1514–1574) completed
‘Libellus de Dentibus’, the first book dedicated exclusively to the description of teeth.127 He was the first
to describe the periodontal ligament, as well as the deciduous and permanent dentitions. Eustachi’s
profound understanding of head anatomy and his amazing eye for the detail led him to link increased
tooth mobility at an advanced age with widening of the space between the root and the alveolar bone.
Similarly remarkable, he prescribed the removal of calculus and granulation tissue using scalers and
curettes, respectively, to encourage re‐attachment of periodontal tissues to loose teeth.358

From scurvy of the gum to Riggs’ disease

Almost two centuries after Eustachi, the French surgeon‐dentist Pierre Fauchard (1678–1761) published
‘Le Chirurgien Dentiste’, a two‐volume book dedicated to the practice of dentistry. Fauchard’s
comprehensive work profoundly influenced the practice of dentistry. He pointed out that any dental
disease can be allocated to one of only three classes, namely: (1) diseases with external cause, (2)
(hidden) diseases that attack those tooth parts embedded in the periodontium, and (3) (symptomatic)
diseases caused by the teeth.113 Critical of the theories accepted by most physicians of his time,
Fauchard postulated a humoral etiology of periodontal disease that is modulated by local factors, e.g.
calculus. To prevent ‘gum disease’, he recommended cleaning the teeth, massaging the gingiva with an
astringent liquid, and washing the mouth with wine and water. Because of the spongy appearance of the
gingiva that had similarity to gingiva he observed in patients with scurvy, Fauchard called the phenotype
‘scurvy of the gums’.
Fifty years later, the Scottish surgeon and scientist John Hunter (1728–1793) published ‘A Practical
Treatise on the Diseases of the Teeth intended as a supplement to the Natural History of those Parts’,
his second and less popular book on teeth and tooth‐related structures. Hunter postulated that gradual
loss of alveolar bone, associated pocket formation and gingival recession would inevitably result in tooth
loss. He considered the process to be disease when it occurred early in life, but the result of natural
aging in the elderly. Among gingival diseases, Hunter distinguished between cases that resembled
Fauchard’s ‘scurvy of the gums’ and cases of overgrown fibrotic tissue.176

Achievements in microbiology, a novel scientific discipline in the 19th century, changed the way
periodontal diseases were viewed. Two German physicians, Robert Ficinus (1809–1852) and Adolph
Witzel (1847–1906), deserve credit for associating bacteria with periodontal tooth loss.63 In Europe, the
term ‘alveolar pyorrhea’ was coined to describe any form of periodontal disorder unrelated to the aging
process. According to Witzel, in patients exhibiting alveolar pyorrhea, the gingiva forms a pocket that
allows bacteria to infect and destroy the underlying periosteum and ultimately alveolar bone. In the
USA, John M. Riggs (1810–1885), also known as the father of periodontics, treated diseased pockets by
painstakingly thorough calculus removal, curettage of soft tissues, and implementation of meticulous
individual oral hygiene. He was convinced that all stages of periodontal disease, from the earliest signs
of inflammation to tooth loss, were attributable to the same local etiology, i.e. calculus. Reportedly,
Riggs’ rigorous procedure healed more than 90% of his patients, a huge improvement over any
previously known treatment. His success was soon recognized. In 1869, the Connecticut Valley Dental
Association passed a resolution acknowledging Riggs as the first person ever to treat gum inflammation
successfully.264 Riggs’ achievement also had a lasting effect on dental terminology; in the USA, the term
‘scurvy of the gums’ was replaced by ‘Riggs disease’. Not for long, however. At the 1877 meeting of the
American Dental Association, the Germany‐born physician Frederick H. Rehwinkel (1825–1889)
presented a paper on ‘pyorrhea alveolaris’, and ever since has been credited for introducing the
European term to the American dental literature.263 The term ‘pyorrhea alveolaris’ was quickly adopted
by the dental community. It persisted deep into the 20th century, despite being rather a poor choice for
the disease it purported to describe.

Focal infection theory

Willoughby D. Miller (1853–1907), whose work was very much influenced by Robert Koch, is best known
for his groundbreaking ideas on the etiology of caries. He also postulated a role for bacteria in the
etiology of alveolar pyorrhea,270 and concluded that, in the presence of predisposing factors, many
bacteria found normally in the mouth can cause periodontal disease (e.g., non‐specific plaque
hypothesis). Miller advocated that such bacteria could also play a role in the etiology of many other
diseases in humans. He coined the expression ‘focus of infection’.271 but stopped short of promoting
eradication of infected teeth to prevent or treat systemic illnesses. This step was made by Frank Billings
(1854–1932), a highly respected American physician and academic leader. Billings and his student and
colleague Edward C. Rosenow (1875–1966) promoted the theory of focal infection in the USA.51, 331 Like
Miller, Billings spent time in Europe, where the germ theory of disease, initiated by the groundbreaking
discoveries of Koch, Lister, Pasteur and other luminaries, was heavily debated. According to Billings’
theory, the germ carrier harbors pleiomorphic microorganisms that may cause disease at any time.
Dissemination of such germs from a latent localized infection to a distant organ would occur through the
blood and lymphatic systems. The focal infection paradigm was quickly adopted by many dentists and
physicians, especially surgeons in the USA. Its clinical implementation, which was further promoted by
substantial improvements in asepsis, led to uncountable unwarranted tooth extractions, tonsillectomies
and other surgical procedures.135 In 1928, Holman publicly questioned the validity of the focal infection
theory.164 Its importance started to decline in the 1930s as evidence accumulated indicating that surgical
removal of suspected foci has no beneficial effect on the medical status of affected patients.65, 326 It is
tempting to speculate about apparent similarities between the focal infection theory and the so‐called
‘systemic link’. However, a closer look at the basis of the two paradigms reveals fundamental
discrepancies, especially with regard to bacterial pleiomorphism and tissue lesion latency.

Periodontal disease classifications
Times of transition and consolidation
At the dawn of the 20th century, the realization that alveolar pyorrhea can be treated led to recognition
of ‘periodontia’ as a dental specialty. The professional organization of periodontists now known as the
American Academy of Periodontology was established in 1914 as the American Academy of Oral
Prophylaxis and Periodontology. In Germany, the ‘Arbeitsgemeinschaft für Paradentosen Forschung’
was formed in 1924 with the goal of establishing an open communication platform for academicians and
practitioners. However, the much needed information exchange was impeded by decidedly inconsistent
terminology. Over subsequent decades, periodontists on both sides of the Atlantic met repeatedly to
develop countless classification systems that reflected scientific progress as well as clinical utility. As a
result of this effort, new nomenclatures were published at arbitrary intervals by professional bodies
such as the American Academy of Periodontology, the American Dental Association, the
Arbeitsgemeinschaft für Paradentosen Forschung and the World Dental Federation, among others. In
addition, classifications were also contributed by individual authors.
One of the major biomedical accomplishments of the 20th century was the recognition that formal
hypotheses can be tested in the clinic. Application of quantitative methods to clinical problem solving,
albeit implemented slowly in most dental disciplines, had profound effects on the classification of
periodontal diseases. The paucity of scientific evidence in support of periodontosis and occlusal trauma
as classes of periodontal disease was initially acknowledged at the 1966 World Workshop in
Periodontics,1 and formalized 11 years later at the International Conference on Biology of Periodontal
Disease. Only two classes of periodontal disease remained – juvenile periodontitis and chronic marginal
periodontitis417 – and these constituted the 1977 American Academy of Periodontology classification
system.
In the meantime, the studies on experimental gingivitis by Harald Löe and his collaborators at the Royal
Dental College in Aarhus, Denmark, ushered in the ‘plaque era’ of periodontology. Using novel index
systems to assess plaque and gingivitis,231, 360 they provided unequivocal experimental evidence for a
direct relationship between the presence of dental bacterial plaque and gingivitis.232, 233, 390 In addition,
they demonstrated the full reversibility of all clinical signs of gingival pathology when oral hygiene was
re‐established. There is no question that the nature and results of these ground‐breaking studies had a
profound effect on most aspects of clinical periodontology.

Moreover, a destructive form of periodontal disease, most frequently observed around the central
incisors and first molars in young people, initiated renewed interest in the disease class previously
known as periodontosis. Baer45 and Manson & Lehner248 published initial clinical reports that were
followed by studies of host defense mechanisms.74, 77, 406 Because it was frequently diagnosed in
adolescent patients, the form was re‐named juvenile periodontitis.At the time of the 1977 International
Conference on Biology of Periodontal Disease, the majority opinion among dentists was that, without
treatment, gingivitis progresses to periodontitis, at a relatively constant rate, ultimately resulting in
tooth loss. This view was challenged when Löe et al.234 presented their results on the natural history of
periodontal diseases. Performed in Sri Lanka in a population with no access to dental services and
virtually no home care, the longitudinal study suggested the presence of three distinct sub‐populations
exhibiting clearly discernible patterns of disease progression: a cohort with no or minimal disease
progression over time, a cohort with moderate disease progression, and a cohort with rapid disease
progression. In most subjects, the presence of plaque and gingivitis did not lead to severe periodontitis
or tooth loss. The centuries‐old belief that linked alveolar bone and tooth loss to ageing was finally
disproved.
These and other findings were reflected in a new classification that was first suggested at the 1986
World Workshop in Clinical Periodontics and modified at the World Workshop in Clinical Periodontics in
1989.2 The revised system distinguished five classes of periodontal disease. In comparison to the 1986
taxonomy, a new class was introduced for periodontal diseases linked to systemic conditions. Moreover,
criteria for disease onset and rate of progression were considered. One of the more obvious
shortcomings of the 1989 classification was the absence of a category for gingival diseases. Also, many
practicing periodontists felt that the emphasis of the classification on patient age at disease onset was
not suitable for long‐term patient care.
Finally, in 1993, the European Academy of Periodontology (now the European Federation of
Periodontology) was founded at the 1st European Workshop on Periodontology. The European Academy
of Periodontology adopted the American Academy of Periodontology’s 1989 classification but suggested
that an improved system should be considered based on three major classes: early‐onset periodontitis,
adult periodontitis and necrotizing periodontitis. Each of these was further defined by secondary
descriptors (distribution within dentition, progression rate, treatment response, relation to systemic
disease, microbiological characteristics, etc.).32

1999 International Workshop for Classification of Periodontal Diseases and
Conditions

The currently used classification (2010) was implemented based on recommendations by the 1999
International Workshop for a Classification of Periodontal Diseases and Conditions (Table 2).29 In
addition to increasing the number of disease classes from five to eight, the revision included several
substantial deviations from preceding classifications. Briefly, gingival diseases were included as an
independent entity (class I). Chronic periodontitis (class II) and aggressive periodontitis (class III)
replaced adult periodontitis and early‐onset periodontitis, respectively, thus eliminating the classifier
‘age’. The refractory class was abandoned, periodontitis as manifestation of systemic diseases (class
IV) was modified and restricted to include only genetic and hematological diseases, and necrotizing
periodontal diseases (class V) replaced necrotizing ulcerative periodontitis. Categories for abscesses of
the periodontium (class VI), periodontitis associated with endodontic lesions (class VII) and
developmental or acquired deformities and conditions (class VIII) completed the new classification
system. Although not perfect, it reflects the current scientific understanding of the nature of periodontal

diseases, as well as the practice of periodontics. In the subsequent sections, the terminology of the 1999
classification will be used as appropriate.
Table 2. 1999 Classification of periodontal diseases and conditions
I: Gingival diseases
A Dental plaque‐induced gingival diseases
B Non‐plaque‐induced gingival lesions
II: Chronic periodontitis
A Localized
B Generalized (>30% of sites are involved)
III: Aggressive periodontitis
A Localized
B Generalized (>30% of sites are involved)
IV: Periodontitis as a manifestation of systemic diseases
A Associated with hematological disorders
B Associated with genetic disorders
C Not otherwise specified
V: Necrotizing periodontal diseases
A Necrotizing ulcerative gingivitis
B Necrotizing ulcerative periodontitis
VI: Abscesses of the periodontium
A Gingival abscess
B Periodontal abscess
C Pericoronal abscess
VII: Periodontitis associated with endodontic lesions
A Combined periodontic–endodontic lesions
VIII: Developmental or acquired deformities and conditions
A Localized tooth‐related factors that modify or predispose to plaque‐induced
gingival diseases/periodontitis
B Mucogingival deformities and conditions around teeth

C Mucogingival deformities and conditions on edentulous ridges
D Occlusal trauma

Classification limitations and next steps

Periodontal disease classification has evolved over a long time period. As such, it is the result of major
paradigm shifts30 that collectively have defined modern periodontology. Needless to say, all
classifications have had their shortcomings, which exposed them to considerable criticism.44, 175, 300, 323, 404
Armitage30 probably put it best when he concluded that: ‘Any attempt to group the entire constellation
of periodontal diseases into an orderly and widely accepted classification system is fraught with
difficulty, and inevitably considerable controversy. No matter how carefully the classification is
developed, and how much thought and time are invested in the process, choices need to be made
between equally unsatisfactory alternatives’.
The purpose of disease classification is to unambiguously link clinical phenotypes, defined by clinical
observations and simple laboratory investigations, with diagnoses and ultimately disease‐specific
therapy (Table 3). The currently used system is a combination of broadly defined classification elements
such as location, etiology and pathology. Some disease classes (II and III) are further refined using rule‐
based criteria, e.g. slight chronic periodontitis is defined by the inclusion criterion ‘1–2 mm of clinical
attachment loss’. Other classes (I, IV and VIII) use relationship definitions rather than operational
definitions for allocation of cases to sub‐classes, e.g. periodontitis as a ‘manifestation of’ Down
syndrome. Technically, allocation of a clinical phenotype to a disease class is achieved using information
collected in a standard periodontal examination. Due to the inherent simplicity of the required clinical
procedures, classification is an easy task for specialists in periodontics.
Table 3. Typical general characteristics of an ideal classification system
• The classification corresponds to the nature of the disease being classified
• Every member of the universe of periodontal diseases (‘periodontal syndrome’) will fit in one
and only one class/sub‐class in the classification system
• The classification is useful
• The number of sub‐classes is not excessive
• The set of classes can be constructed using a systematic procedure

However, as mentioned above, the current classification has also received challenges. Of general
concern is that some clinical phenotypes do not meet the classification criteria of any particular disease
class. Examples have been described in the literature,175, 300 and concern non‐inflammatory destructive
periodontal disease or atrophy. A weakness of many disease classifications is substantial overlap among
classes. This occurs when the key properties of classes are too broadly defined. In such situations,
clinical phenotypes cannot be allocated unequivocally, and mis‐classification is possible. An example is
the definition of aggressive periodontitis (class III) as ‘rapid attachment loss and bone destruction’.
Here the critical identifier refers to a subjective, temporal interpretation of a cross‐sectional finding
rather than objective information that can be obtained from patient examinations and records.

However, there is no universal agreement on threshold rates for rapid attachment loss and bone
destruction. To mitigate the risk of mis‐classification, selected biochemical (e.g. interleukin‐1β and
prostaglandin E2) and microbiological (e.g. Porphyromonas gingivalisand Aggregatibacter
actinomycetemcomitans) secondary identifiers have been proposed.221 Another concern is the
sensitivity and specificity of the methods used to collect patient information. Data on change in probing
depth, clinical attachment and radiographic bone level are collected as the result of disease history. The
methods used to generate such information lack the sensitivity required to detect the subtle sub‐clinical
changes that occur before tissue damage is clinically obvious. In addition, they are associated with
substantial measurement error, which affects diagnostic specificity.
Our understanding of the fundamental mechanisms involved in onset and progression of most diseases,
including those affecting the periodontium, remains incomplete. The already substantial amount of
knowledge acquired from clinical and laboratory research regarding the etiology and pathomechanisms
responsible for periodontal diseases has not yet paid off in terms of development of potent preventive
and therapeutic measures for the individual patient. However, this situation will change. Progress
achieved in the post‐genomic disciplines of transcriptomics, proteomics, metabolomics and systems
biology will permit a much more accurate and precise characterization and definition of disease at the
phenotype level. In the not so distant future, such information could be used for identification of
phenotypic differences among patients suffering from the same disease, subsequently leading to
individualized, patient‐specific therapies.239

Etiology

It is accepted that dental plaque microorganisms existing in the form of biofilms are primary etiological
agents of periodontal diseases. Biofilms are matrix‐enclosed bacterial communities that adhere to each
other and to surfaces or interfaces. Enormous advances in biology and technology have provided ever
more sophisticated tools for the investigation of dental biofilms. Introduction of the GasPak system59
and the anaerobic glove box27 allowed discovery of numerous fastidious anaerobic planktonic species in
the oral cavity.274, 365 Due to this advancement in anaerobiosis, coupled with epidemiological data, it was
possible to associate a population shift toward certain gram‐negative anaerobic species in dental plaque
biofilms with the initiation and progression of periodontal diseases. However, it was the application of
DNA‐based assays, polymerase chain reaction and confocal microscopy71, 206, 212, 217, 304, 366 that deepened
our understanding of the formation, maturation and ecology of dental plaque biofilms.
The epithelia lining the mouth and the exposed tooth surfaces constitute the adherence substrate for
oral biofilms (Fig. 1). Oral bacteria are initially acquired by contact with an infected family member at
birth or at later life stages.401 The conditions for bacteria to initiate successful colonization vary greatly
depending on tissue type, location, and exposure to external shear forces. The gingival sulcus, and
especially the col region, which forms the bridge between adjacent gingival papillae, offer protected
niches that favor bacterial settling. Pioneer colonizers include oral species of the
genera Streptococcus, Veillonella, Prevotella, Neisseria, Gemella, Actinomyces and others.302 During
biofilm maturation, bacteria interact with each other within and between species via surface‐associated
structures (co‐aggregation), leading to a unique spatial organization.229 As part of a sophisticated
ecological system, biofilm residents communicate through exchange of genetic information and quorum
sensing, a mechanism that allows coordination of their gene expression according to population
density.47, 379 In addition, biofilm bacteria facilitate processing and uptake of nutrients, and protect
themselves from other species (by producing bacteriocins), the host and harsh environments,245
allowing them to establish stable communities.214

Figure 1. Properties of bacterial biofilms. Bacterial cells in a biofilm are held together by a matrix
composed of extracellular polysaccharides, proteins, and other compounds. Biofilm development occurs
in response to extracellular signals, both environmental and self‐produced. Biofilms protect bacteria
from a wide array of insults as diverse as antibiotics, predators, and the human immune system. The
biofilm shown in the figure was grown for 3 days on a human enamel sliver worn by a healthy
volunteer in the region of the maxillary premolars and molars. The surface to be imaged was facing
towards the natural teeth to simulate retention areas. The biofilm was stained using fluorescent in
situ hybridization (FISH) to show streptococci (yellow) and all bacteria (red). Reflected imaging (blue) was
used to show the surface of the plaque and the slime matrix between the bacteria in the biofilm. The
plaque biofilm was composed of dense clusters of streptococci interspersed with clusters formed by other
bacteria. The scales on the x, y and z axes are in 1 μm increments. Biofilm image courtesy of Drs.
Christiane von Ohle (Department of Conservative Dentistry, Tübingen, Germany) and Paul Stoodley
(National Centre for Advanced Tribology Southampton, Southampton University, UK).
Mature dental biofilms can host a large variety of bacterial genera. Molecular detection of the
microflora in the oral cavity has led to identification of approximately 700 bacterial species or
phylotypes.12, 212, 304 Approximately 50–60 species can be identified in a typical plaque sample when 16S
rRNA probes are used.329 16S rRNA is a highly conserved gene sequence that permits estimation of
evolutionary distance and relatedness of organisms.78 Species compositions of dental biofilms vary
greatly from sample to sample and are site‐specific.305 From initial colonization to formation of mature
and potentially pathogenic supra‐ and subgingival communities, dental biofilms pass through several
stages, including colonization, growth of commensal bacteria, and integration and invasion of
pathogenic species.207 Such opportunistic pathogens co‐exist with other biofilm residents until changed
environmental conditions favor their expansion and expression of their pathogenic properties. The
bacterial composition of mature biofilms sampled in the gingival sulcus of periodontally healthy subjects
over an extended time period shows a high level of temporal stability. In contrast, in subjects whose
clinical status changes from health to disease or vice versa, many bacterial species disappear or
emerge.213, 368, 384 Likewise, periodontal diseases are considered to be opportunistic polymicrobial
infections. Putative bacterial pathogens associated with periodontal diseases have been identified in
subgingival biofilms. These include A. actinomycetemcomitans, P. gingivalis, Tannerella
forsythia, Treponema denticola, Prevotella intermedia, Fusobacterium nucleatum, Eikenella
corrodens, Campylobacter rectus, Parvimonas micra (previously Peptostreptococcus micros)
and Streptococcus intermedius. Three species, P. gingivalis, T. forsythia and T. denticola, have been

designated as ‘the red complex’,367 and are implicated in progression of chronic periodontitis. Numerous
virulence factors, which can initiate and modulate pathways of the host response, were identified and
characterized from these species.165, 386 P. gingivalis(previously Bacteroides gingivalis), a gram‐negative
black‐pigmented, immotile obligate anaerobe, is a late or secondary colonizer that depends on the
presence of other biofilm species.281 Its virulence potential is characterized by: (1) adhesion and co‐
aggregation mediated by fimbriae, vesicles, several hemagglutinins and outer membrane proteins, (2)
evasion of host responses mediated by capsule lipopolysaccharides, and immunoglobulin and
complement proteases, and (3) tissue damage mediated by a large number of peptidases that enable
tissue invasion and destruction, and production of toxic metabolic end‐
products.281 T. forsythia (previously Bacteroides forsythus) is a fastidious, non‐motile, spindle‐shaped,
obligate anaerobic gram‐negative rod whose growth in biofilms depends on co‐aggregation
with P. gingivalis or F. nucleatum. It secretes proteolytic enzymes and sialidase, and can induce
apoptosis. Furthermore, T. forsythia can adhere to and invade epithelial cells and extracellular matrix
components via the cell surface‐associated BspA protein. The invasion is enhanced in the presence
of P. gingivalis.177 In addition, T. forsythia possesses a unique surface structure called a surface (S‐) layer
that is involved in hemagglutination and adherence/invasion of epithelial cells.335 T. denticola is a gram‐
negative, aero‐tolerant anaerobic spirochete. It is a late colonizer, and adheres readily to other bacteria,
such as P. gingivalis, T. forsythia and F. nucleatum, using various adhesins. T. denticola also possesses
numerous proteinases and peptidases. The functions of selected virulence factors identified from these
periodontal pathogens have been validated by construction of isogenic mutants and animal studies.166
Aggregatibacter actinomycetemcomitans (previously Actinobacillus actinomycetemcomitans)285 is a
putative pathogen that has been associated with aggressive (previously known as ‘juvenile’) forms of
periodontitis.115, 363, 429 The oral cavity is its only known natural habitat. It is isolated regularly and in large
numbers from various oral mucosal surfaces, even in toddlers and in the absence of periodontal
pathology.218, 385 Serotype b, one of five defined serotypes, can be isolated primarily from periodontal
pockets in subjects with localized aggressive periodontitis.428 In addition to its ability to
colonize, A. actinomycetemcomitans can invade epithelial cells,265 secrete a leukotoxin42, 157 and induce
apoptosis.192 A. actinomycetemcomitans shows clonality in virulence, as leukotoxin production is greatly
increased in clone JP2.199 This clone belongs to serotype b and has a 530 bp deletion in the promoter
region of the leukotoxin gene operon. This deletion is most likely responsible for the increased toxin
production. Originally discovered in an 8‐year‐old Moroccan child with aggressive periodontitis,149 the
clone has also been isolated from Africans with a history of aggressive periodontitis in other parts of the
world. The restriction of infection with JP2 to individuals of West‐ and North‐African descent implies
great colonization stability and a vertical transmission pathway from mother to child. Moreover, this
allowed the investigators to track JP2’s emergence on the African continent back in time for hundreds of
years.199 While infection with JP2 is a somewhat unique finding, it sheds light on the importance of
specific bacteria in certain forms of periodontal disease, as well as the potential value of microbiological
screening309 for early detection in susceptible subjects.

Pathogenesis

The characteristic gingival and periodontal lesions are the result of biofilm‐induced, orchestrated
inflammatory responses involving the innate and adaptive arms of the immune system. Inflammation
that remains limited to the gingiva is the outcome of a well‐balanced symbiosis between biofilms and
the host tissues, while periodontitis is the result of breakdown of this symbiosis. Moreover, it may be
speculated that even the most common forms of periodontal diseases are merely analogous phenotypes
of different pathogenetic pathways, initiated by biofilm products, of which only a few lead to tissue
destruction in susceptible hosts. Much progress has been made at all levels of inquiry towards

understanding these pathways.209, 295, 296, 298 Figure 2 shows a highly simplified model of the inflammatory
pathway that can lead to tissue destruction, and it is explained below.

Figure 2. Inflammatory pathways are initiated by biofilm bacteria or products, and ultimately produce a
tissue response, i.e. gingivitis or periodontitis. The type and strength of the response are determined by
pathogen‐associated molecular patterns (PAMPs) and the subject’s genetic make‐up, and modulated by
the presence or absence of modifying factors, including diabetes, obesity, smoking, and others. For
example, the PAMP lipopolysaccharide from gram‐negative bacteria (e.g. Porphyromonas
gingivalis or Tannerella forsythia), first binds via the CD14 receptor to Toll‐like receptor 4, a pattern
recognition receptor (PRR) that is expressed on polymorphonuclear leukocytes, as well as gingival and
junctional epithelia. Activation of Toll‐like receptor 4 also requires the presence of protein MD2, and
engages a set of response proteins. Subsequently, intracellular signal cascades are turned on, resulting in
a Toll‐like receptor‐specific reaction. Transition from the innate to the adaptive response is initiated by
Toll‐like receptor‐triggered cytokine and chemokine production, and involves activation of antigen‐
presenting cells, as well as T‐cell differentiation and regulation.
Basically, dental plaque biofilms are in constant interaction with their underlying substrates, i.e. the
tooth surface, junctional epithelium, gingival epithelium and pocket epithelium. They receive nutrients
from the saliva, crevicular fluid, cell debris and food. Considering biofilms a nuisance, without any
benefit to the host, may be a big mistake. Not only do biofilms affect the host, there is mounting
evidence that the host’s responses similarly influence the metabolism and composition of biofilms. In a
healthy person, host defense and biofilms co‐exist in a mutually beneficial symbiotic state.167, 253
Bacteria are released continuously from dental biofilms, and to a large extent are eliminated before they
elicit any host response. Significant bacterial invasion is not observed in subjects with clinically healthy
periodontal tissues. Various physiological mechanisms are in place to maintain tissue integrity; bacterial
products are rinsed off by the continuous saliva flow, crevicular fluid flushes the gingival sulcus, and the
high turnover of the junctional and gingival epithelia eliminates bacteria‐loaded superficial cells.60, 348
In addition to the mechanical cleansing action, highly potent first‐line antimicrobial defense systems can
sense and destroy intruders. Such systems include peptides found in the saliva (histatins, cathelicidins
and others), epithelium, neutrophils,93 and molecules described as pattern recognition receptors
(PRRs).73 α‐defensins are observed in the junctional epithelium, where they are associated with
polymorphonuclear leukocytes. These cells constantly migrate towards the gingival sulcus, responding

to a gradient of interleukin‐8 that is expressed in the junctional and sulcus epithelium.395 β‐defensins are
found in gingival and pocket epithelia, where they are constitutively expressed.211 In addition to
exhibiting excellent antibacterial properties, defensins can activate the complement cascade, up‐
regulate production of the chemokine interleukin‐8 in epithelial cells, and attract immune cells.254 PRRs
are typically found on the surface of polymorphonuclear leukocytes, macrophages, dendritic cells,
endothelial cells, mucosal epithelium cells and lymphocytes.189 They include two functional families.
Endocytic PRRs are located on the surface of phagocytes. They facilitate the attachment of
microorganisms, leading to their engulfment and destruction. Signaling PRRs are located on the surface
of a greater variety of cells. They recognize structurally highly conserved pathogen‐associated molecular
patterns (PAMPs) on microorganisms. PAMPs include lipopolysaccharide, teichoic acids, sugar
residues, N‐formyl peptides and others. Binding of PAMPs to PRRs promotes the synthesis and secretion
of intracellular regulatory molecules such as cytokines that are crucial for initiating innate immunity and
adaptive immunity.
Recently, Toll‐like receptors, a subgroup of the signaling family of PRRs, were identified in periodontal
tissues.246 Interaction between a PRR and its PAMP leads to a rapid cascade of events, including
formation of a PRR–ligand complex that can be internalized, activation of Toll‐like receptors and NFκB,
and transcriptional activation resulting in the synthesis of reactive oxygen species, reactive nitrogen
species, cytokines (interleukin‐1, interleukin‐12 and tumor necrosis factor‐α), and chemokines
(interleukin‐8, monocyte chemoattractant protein‐1, regulated on activation, normal T cell expressed
and secreted (RANTES)). These compounds trigger an immediate inflammatory response, and enable
migration of additional leukocytes from the blood to the site of inflammation. CD14 is another PRR that
is expressed on polymorphonuclear leukocytes, macrophages and monocytes. It enhances the ability of
Toll‐like receptor 4 to respond to lipopolysaccharide. The complex formed of CD14, lipopolysaccharide
and Toll‐like receptor 4 increases the production of cytokines and chemokines, leading to
inflammation and activation of the complement cascade and the coagulation pathway. Finally, Toll‐like
receptors instruct dendritic cells to initiate a highly differentiated, specific T‐cell response.14 Thus,
defensins and PRRs not only neutralize microbial components, they also constitute an important link
between innate and adaptive immune responses.
Increased vascular leakage and activation of serum protein systems potentiate the local acute
inflammatory response. Gingival crevicular fluid flows at an increased rate.108, 134 During early phases of
lesion development, a dense polymorphonuclear leukocyte‐dominated infiltrate is found in the biofilm‐
adjacent gingival compartment. To destroy potential intruders, polymorphonuclear leukocytes release
proteases, prostaglandins and other inflammation‐enhancing molecules, as well as highly potent
reactive oxygen and nitrogen species. These effectors do not discriminate between host and bacteria,
resulting in collateral damage to gingival connective tissue. A successful inflammatory response
eliminates the infectious agent and initiates tissue repair. However, if the infection prevails, as a result
of persisting inflammation and instructed by macrophages and dendritic cells, cells of the adaptive
immune system appear, and the lesion takes on chronic traits. T‐cells and B‐cells start to accumulate,
and ultimately dominate the lesion. Their proportions are determined by the type of immune response
elicited by the antigens and the presence of modulating cytokines. Plasma cells develop from B cells
and produce antibodies in response to bacterial antigens and mitogens. In a typical gingival lesion, T
cells predominate. T‐helper cell subsets (Th1 or Th2) develop from T cells depending on the types and
amount of cytokines released. The balance between T‐helper cell subsets is critical for the
immunoregulation of periodontal disease.356 Th1 cells predominate in stable periodontal lesions, but a
strong presence of Th2 cells indicates a shift towards lesion progression, with a predominance of plasma
cells.355

The local physiological defense mechanisms are very robust and exhibit substantial redundancy. In fact,
many people show minimal or no periodontal destruction despite experiencing gingivitis as a result of
lifelong poor oral hygiene.234 However, robust systems are weak when their non‐redundant components
are attacked,204 resulting in deficiencies in the immune system. Such attacks may have critical
consequences for periodontal tissue integrity, as illustrated in patients with (genetic or acquired)
immune deficiencies. In particular, class IV.B cases of periodontal disease have been associated with
mutations in the genes encoding for polymorphonuclear leukocyte elastase (severe congenital
neutropenia), Chediak–Higashi syndrome 1 protein (Chediak–Higashi syndrome), integrin‐β2
(leukocyte adhesion deficiency), cathepsin C (Papillon–Lefèvre syndrome) and others.145
Resorption of the alveolar bone is a defining characteristic of many periodontal diseases. Several
inflammatory pathways can result in bone destruction.387 Macrophages, in addition to processing and
presenting antigens for activation of the specific immune response, also produce cytokines and enzymes
that induce bone resorption. Recently, an alternative mechanism was described that involves three
members of the tumor necrosis factor receptor family: the receptor activator of NFκB (RANK), the
receptor activator of NFκB ligand (RANKL) and osteoprotegerin.193, 230 The ligand RANKL is found on
osteoblasts, but is also expressed by lymphocytes present in the inflammatory infiltrate. RANK is
expressed on mature osteoclasts and their precursors, and osteoprotegerin is synthesized by
mesenchymal cells. The interaction of RANK and RANKL initiates the differentiation and activation of
bone‐resorbing osteoclasts, and can be blocked by the decoy ligand osteoprotegerin. RANKL and
osteoprotegerin are found in crevicular fluid, and their relative levels appear to predict disease.54

Epidemiology
General trends

Gingival and periodontal diseases occur globally and among virtually all populations that have been
studied to date.19 Clinical signs of periodontal destruction may be absent in individuals of any age, but
there is little evidence supporting the existence of periodontitis‐resistant populations. However, two
defined apparently resistant cohorts with no access to dental care were described in Namaqualand and
Crossroads (South Africa).13, 324 They showed minimal clinical periodontal breakdown at any age, despite
the presence of a heavy plaque load and gingivitis.
The World Health Organization performed extensive surveys of the periodontal status of potentially
under‐served populations around the globe, especially in developing countries.307 Using the Community
Periodontal Index for Treatment Needs to assess prevalence, a majority of subjects examined had
gingivitis and 10–15% of adults had periodontal pockets ≥6 mm deep. In contrast to common belief,
periodontal diseases are not the most important factor for tooth loss in many Asian and most African
populations. In fact, surveys have indicated that, in Africa, most people retain the majority of their teeth
throught their lives.43, 83
In the USA, based on estimates obtained from the National Health and Nutrition Examinations Surveys
performed from 1988 to 1994 (NHANES III),278 the overall prevalence of moderate to severe signs of
periodontitis among adults was 7.3%, corresponding to one affected adult person in 14.19, 53
Approximately one in five adults had slight periodontitis, one in ten had moderate periodontitis, and
one in 30 showed signs of severe periodontitis. The prevalence of periodontitis increased with
population age, but the prevalence of more severe forms peaked at 70 years and leveled off
thereafter.19 Periodontitis was more frequently diagnosed in men than in women. Substantial racial and
ethnical disparities were observed. Adult black people were almost twice as likely to exhibit
periodontitis as white adults, suggesting a significant racial gap.53

In the analysis of the more recent NHANES 1999–2000 data,53 the overall prevalence of moderate to
severe periodontitis was only 4.2% (compared to 7.3%), suggesting a potentially substantial reduction in
disease burden over the past decade. Surveys performed in Europe have corroborated the suspected
‘secular trend’ of prevalence reduction in periodontal diseases among adults.334, 362 A comparison over a
30‐year period of the prevalence of various clinical signs of periodontal disease in Swedish subjects aged
20–70 years revealed remarkable changes (Fig. 3).169 Over the surveyed period, the proportion of
periodontally healthy individuals improved from 8% to 44%. The increment compensated for the
decrease in the proportion of individuals with gingivitis or moderate alveolar bone loss. In contrast, the
proportion of subjects exhibiting signs of severe periodontal disease was small and did not change over
time. Improvements in oral hygiene, changes in lifestyle and adoption of less risky behavior, in particular
recognition of deleterious smoking effects, have been proposed to explain the unexpected decline.
However, much more work is undoubtedly required to confirm and understand this highly desirable
trend.

Figure 3. An improvement in alveolar bone index was observed over a 30‐year time period in
Scandinavians, as indicated by the blue (1973) and red (2003) bars. Mean alveolar bone indices were
estimated from radiographs obtained in cross‐sectional studies performed in 1973 and 2003. Age groups
from 20 to 70 years are shown. Data from.169

Aggressive forms of periodontitis

Aggressive forms of periodontitis are defined by rapid localized or generalized loss of the supportive
periodontal structures, and occur in family clusters in otherwise medically healthy subjects.221
Aggressive forms can affect the primary or permanent dentition. Typically, susceptible patients are less
than 30 years old at disease onset.16 The similar phenotypes of aggressive periodontal disease are
probably the clinical expression of multiple disease forms with discrete etiologies.
The reported prevalence of early‐onset aggressive periodontitis varies from study to study. The
comparability of the data is affected by the somewhat ambiguous disease definitions and the various
diagnostic techniques used. A review concluded that aggressive forms of periodontitis have a low
prevalence in most regions of the world, occurring in 0.1–1.0% of the population.20 For reasons that are
unclear at present, this disease form is seen substantially more frequently among young black subjects.
A prevalence of 2.6% was reported in a sample representative of high school students in the USA.15
Even higher disease prevalences of 6.5% and 7.6% were observed in two cohorts of adolescents and
young adults in Uganda18 and Morocco,149 respectively. These subjects were carriers
of A. actinomycetemcomitans clone JP2, which is endemic in Morocco. Carriers of the JP2 clone, who

were free of clinical disease signs at the first examination, had a relative risk of 18.0 (95% CI 7.8–41.2) of
experiencing periodontal attachment loss during the 5‐year observation period.150
Although earlier reports by Saxén338 showed a female majority among subjects with early‐onset
aggressive periodontitis, a more recent national survey conducted in the USA did not corroborate this
observation.235 Furthermore, based on the results of a genetic segregation analysis performed in 100
families in the USA, the aggressive disease trait has an autosomal dominant inheritance pattern.249 This
contrasts with the autosomal recessive inheritance pattern identified in northern Europe,339 suggesting a
different pathway to disease for each of the two populations.

Necrotizing periodontal diseases

Necrotizing periodontal diseases feature ulceration and necrosis of the interdental papillae,
spontaneous bleeding, pain and a removable pseudomembrane.4 Advanced cases involve alveolar bone
resorption, may be generalized, and may lead to fever, malaise and lymphadenopathy.276 Necrotizing
periodontal diseases are observed frequently in parts of Africa, Asia and Latin America, mainly in socially
disadvantaged children. For example, in an urban South African clinic population, the prevalence of
acute necrotizing ulcerative gingivitis was 3%. Males were more frequently affected than females.
Seventy‐three per cent of the patients were children between 5 and 12 years old. The seasonal
occurrence varied greatly, with most cases diagnosed in the summer (relative risk 6.57; 95% CI 4.96–
8.70).28 In contrast, necrotizing periodontal disease is now rarely observed in the general population of
Europe and North America, as confirmed in a recent study among 18‐ to 22‐year‐old military recruits in
Switzerland.82
A high prevalence of necrotizing periodontal disease has been observed in HIV‐infected
subjects.223, 306, 314 Based on this finding, the presence of necrotizing periodontal disease has been
recommended for use as a surrogate marker of HIV‐associated immune deficiency and AIDS.125

Risk modifiers

Development and progression of periodontal disease in an individual are ‘personalized’ by a number of
endogenous and exogenous factors (Table 4). Assessment, knowledge and proper management of these
factors facilitate the prevention of disease or its containment in the case of an existing periodontal
condition. An intelligent algorithm that estimates the risk for periodontal disease based on easily
accessible clinical information was developed, validated and implemented in practice.299, 301
Table 4. A selection of risk modifiers of chronic and aggressive periodontitis
Risk modifier
Age of patient
Bleeding on probing
Diabetes mellitus
Furcation involvement
History of periodontal surgery
Probing (pocket) depth

Radiographic bone level
Restoration below the gingival margin
Root calculus
Single‐nucleotide polymorphisms
Smoking history
Vertical bone lesions

Smoking

An association between smoking and alveolar bone loss was first reported by Waerhaug’s group in the
late 1950s.31 Cigarette smoking was identified to be an age‐independent risk indicator for periodontal
disease in the Tecumseh Community Health Study in Michigan.378 This greatly increased risk of smokers
experiencing periodontal breakdown was confirmed in many studies.36, 104, 163, 255, 315 An analysis of the
NHANES III survey data concluded that smokers have a four times greater risk of periodontitis than
non‐smokers.17 The data suggest a dose–effect relationship between the number of cigarettes smoked
per day and the likelihood of developing periodontitis. The research further estimated that more than
40% of cases of periodontitis among adults can be attributed to current cigarette smoking. Of major
clinical relevance is the observation that smoking impairs wound healing following scaling and root
planning,137, 182, 403 periodontal surgery24, 111, 376, 396 and guided tissue regeneration procedures.240
Mechanisms for smoking‐induced adverse effects have been postulated, but the precise molecular
pathways remain to be identified.46, 49 Smoking is unquestionably a major risk modifier for most
inflammatory periodontal diseases.

Genetics

It has been well established from twin studies that genetic factors contribute substantially to the risk of
chronic periodontitis.84, 266, 267 A population‐based study275 in more than 10,000 Swedish twin pairs
estimated that genetics‐attributable contributions to the cummulative risk of periodontal disease
amounted to 39% (95% CI 31–47%) and 33% (95% CI 24–42%) in women and men, respectively.
Furthermore, the magnitude of the effect was strongly influenced by age and smoking status, suggesting
substantial gene–environment interaction.
Based on the currently available evidence, chronic and aggressive forms of periodontitis are not
associated with single gene mutations or acquired molecular abnormalities. However, DNA sequence
variations in genes that result from alteration of a single nucleotide can substantially affect the disease
phenotype. Single‐nucleotide polymorphisms are thought to play a role in periodontal diseases.10 The
commercial availability of high‐throughput, low‐cost technology has boosted research in genome‐based
risk factors for complex diseases. As a result, the association of numerous polymorphisms with specific
forms of periodontal disease was investigated.58, 114, 120, 130, 181, 208, 380, 383, 422, 423 Examples of single‐
nucleotide polymorphisms that were considered in such studies include those in interleukin‐1,
interleukin‐6, interleukin‐10, interleukin‐12RB2, Fc‐γ, matrix metalloproteinase‐9 and tumor necrosis
factor‐α, to name but a few. In addition to obtaining a better understanding of the disease process, such
polymorphisms may be used as diagnostic or prognostic markers. The PST™ genetic test (Interleukin
Genetics Inc., Waltham, MA, USA) has been offered to patients with periodontitis. It tests for single‐
nucleotide polymorphisms of interleukin‐1 genes, and has shown moderate sensitivity and specificity in

predicting disease progression in non‐smokers. The test’s cost‐effectiveness was investigated using a
mathematical model.160 The authors’ conclusion that more benefits would result if risk‐specific
treatments were available is very much to the point.
Epigenetic alterations to the genome may also play a significant role in disease expression. These
changes involve both methylation of DNA and post‐translational modification of histone proteins. The
epigenetic profile is modified by the environment over time, and may have substantial implications for
periodontal disease expression.421

Diabetes

Estimates suggest that approximately 7% of the total population in the USA have diabetes, and the
prevalence is increasing.66 Subjects with a history of type 2 diabetes mellitus have a higher prevalence
and severity of periodontitis, as shown in Pima Indians.110 In another study, 25‐ to 74‐year‐old diabetics
had significantly increased likelihood of experiencing attachment loss.136 Recently, an increased
prevalence of periodontitis was shown in children and teenagers with type 1 diabetes compared to
age‐matched controls.217 Subjects with poor glycemic control showed faster recurrence of periodontal
pockets after periodontal treatment than non‐diabetic controls.389 Westfelt et al.416 compared the
outcomes of periodontal surgical treatment in subjects with well‐controlled type 1 and 2 diabetes with
those in sex‐ and age‐matched controls over a 5‐year period. All subjects had moderate to advanced
forms of chronic periodontitis. The results showed no difference between the two treatment groups,
suggesting that well‐controlled diabetics can maintain healthy periodontal conditions. There has been
increased interest in the question of whether or not treatment of periodontal diseases leads to
improved glycemic control in diabetic patients.178 Nine controlled clinical trials were performed in an
attempt to answer this important question, and the results were summarized meta‐analytically.94 The
overall results indicated that periodontal treatment led to a statistically significant reduction in the
surrogate marker glycosylated hemoglobin (HbA1c). However, the authors’ enthusiasm about this
favorable finding was guarded because of the small size of the reduction (<1%) and its lack of
robustness. They therefore concluded that there is still insufficient evidence for global recommendation
of periodontal treatment as an effective measure to reduce glycosylated hemoglobin (HbA1c) in adult
subjects.

Obesity

Obesity is a major risk contributor to disease and death worldwide. More than 60% of adults in the USA
are overweight, and approximately 30% are obese.151 Close relationships have been established
between obesity and diabetes, hypertension, coronary heart disease and stroke, and cancer.146 Body fat,
which is accumulated to excess in obese people, is produced by adipocytes. In addition to producing fat,
these cells also release molecules that affect insulin resistance, and secrete hormones and cytokines,
leading to a hyperinflammatory state. In a brief editorial note, Saito et al.336 described their observation
that apparently healthy Japanese subjects with a BMI > 25 kg/m2 had a significantly higher relative
risk of periodontitis than subjects with a BMI < 20 kg/m2. The association between obesity and
periodontitis was subsequently substantiated by more extensive studies in various populations.227, 310, 424

Pregnancy

The female body is subject to substantial hormonal fluctuations, especially during pregnancy. The most
remarkable hormonal change during pregnancy is the increasing production of estrogens and
progesterone, which levels off approximately one month before delivery. By that time, estrogen blood
levels have risen more than 100‐fold. In addition, the type of estrogen secreted changes from estradiol
to the less potent estriol. These hormones are mostly produced by the placenta, and the levels revert to
pre‐pregnancy levels within a few days after delivery. An increased prevalence and severity of gingival

inflammation were reported in pregnant women.231, 247, 375 These changes appear to be independent of
changes in plaque amount168 and are reversible.140 About one pregnant woman in 20 develops a highly
vascular, edematous lesion known as pyogenic granuloma. The lesion occurs typically during the first
two trimesters, and has a strong tendency to recur if excised during pregnancy. Although hormones are
likely to play a significant role in the development of pyogenic granuloma, its etiology remains largely
unknown.216

Medications

Early studies on the effect of oral contraceptives on parameters of periodontal health reported an
increased prevalence and severity of gingivitis in subjects who were taking contraceptives than in
controls.250 The contraceptives used by study participants contained high doses of estrogen, progestin,
or both. In contrast, the most frequently used products at the present time are low‐dose combination
preparations of estrogen (≤50 μg) and progestin (≤1 mg). A more recent study382 used information
collected in NHANES I and III to investigate the relationship between oral contraception use and
periodontal parameters. The thorough analysis rejected the previously held notion that women on oral
contraception are at higher risk of experiencing clinical signs of gingivitis or periodontitis.
Certain anticonvulsants (e.g. phenytoin), immunosuppressants (cyclosporine) and calcium channel
blockers (e.g. nifedipine) have been associated with gingival enlargement.7 The prevalence of this side‐
effect varies from 5% to 50% in adults.79 For cyclosporine, the highest prevalence of gingival overgrowth
was observed in children191 and decreased with increasing patient age.152 The severity ranged from small
single lesions to massive growths that impaired function and esthetics.147 The pathogenesis of drug‐
influenced gingival enlargement remains unresolved, although a multitude of contributing factors
appear to be involved, including integrins, cytokines and matrix metalloproteinases. An interesting
hypothesis proposed involvement of single‐nucleotide polymorphisms of the MDR1 gene, which
encodes the drug‐efflux pump P‐glycoprotein. This effect was observed in a clinical study98 that found
severe cyclosporine‐induced overgrowth in patients carrying the MDR1 C3435T mutation.

Nutrition

For many centuries, a deficient diet was considered a cardinal factor in the development of periodontal
diseases. The hypothesis was based on anecdotal evidence, and held up to its premise until animal
experiments permitted its scientific test. Glickman126 was among the first to investigate the effect of
vitamin C on the periodontium in guinea pigs. His experiments confirmed that diets lacking certain
vitamins or minerals can affect the development of periodontal tissues and bone. Specifically, the
author concluded that a diet deficient in vitamin C resulted in generalized alveolar changes but was
not responsible for periodontal pocket formation. Recently, Nishida et al.284 reassessed the relationship
between dietary vitamin C intake and periodontal disease using the powerful NHANES III database.
They found that persons with low vitamin C intake (<30 mg/day) had a slightly increased likelihood of
developing periodontitis when compared to a reference group with elevated intake (>180 mg/day).
Diets rich in whole grain have been associated with lower risk of diabetes and cardiovascular disease.226
This desirable effect is probably the result of improved insulin sensitivity and improved glycemic
control.180 Merchant et al.262 used information gathered in the Health Professionals Follow‐up Study
(HPFS) to investigate the relationship between intake of whole grain, refined grain or cereal fiber and
risk of periodontitis. After 14 years of follow‐up, men who consumed 3.4 servings per day (median) of
whole grains were 23% less likely to be diagnosed with periodontal disease than those who consumed
0.3 servings per day (median). These intriguing results were further confirmed in a study using data from
NHANES III that found an inverse association between serum total antioxidant capacity and
periodontitis.69, 70

Systemic effects of periodontal disease

After several decades of relative absence from the scientific literature, new reports linking indicators of
dental health with an increased risk for a variety of systemic diseases emerged in the 1980s and 1990s.
Examples include associations with myocardial infarction.257, 361 stroke,236, 381 cardiovascular disease,102
peripheral vascular disease,261 adverse pregnancy outcomes95, 289 and pneumonia.118, 340, 341 The
possibility that periodontal and other diseases of the human body could be linked created broad‐based
excitement among the dental community and beyond, and ushered in the era of periodontal
medicine.418 As a result, in a worldwide effort, hundreds of clinical and laboratory studies have been
performed, leading to a much deeper understanding of periodontal diseases as part of overall health.
The foundation for an etiological role of periodontal diseases in general health is based on two
assumptions. First, bacteria released from biofilms located in periodontal pockets can enter the
bloodstream through ulcerations of the pocket epithelium and colonize other body parts, especially in
patients with compromised immunity.200, 342 Second, periodontal pathogens elicit inflammatory
reactions in the affected tissues, stimulating the release of pro‐inflammatory cytokines or acute‐phase
proteins, and contributing to systemic inflammation, possibly atherogenesis, and other
pathology.96, 200, 303
Although many published (frequently small‐scale) studies have reported statistical associations between
parameters of oral health and systemic disease, the all‐important cause/effect relationship awaits
confirmation in large‐scale longitudinal epidemiological and interventional studies. Examinations of the
link between periodontitis and coronary heart disease using information collected in NHANES I did not
show the expected strong association.171, 172 Furthermore, a review of nine cohort studies found no or
only weak associations after controlling for smoking or lifestyle factors.174 The concern that confounding
could mask the study outcome received additional support in the 6‐month pilot trial of the National
Institutes of Health‐sponsored Periodontitis and Vascular Events (PAVE) study.293 The trial showed that a
beneficial effect of periodontal treatment on the surrogate marker hs‐C‐reactive protein was achieved
only in non‐obese subjects with cardiovascular disease, whereas it was not observed in obese subjects.
Another National Institutes of Health‐funded multi‐centered study, the randomized controlled
Obstetrics and Periodontal Therapy (OPT) trial, investigated the effect of non‐surgical periodontal
treatment on pre‐term birth rates in more than 800 pregnant women exhibiting clinical signs of chronic
periodontitis.268 The investigation confirmed the safety and effectiveness of standard periodontal
treatment in pregnant women, but did not detect significant treatment‐induced reductions in the rate of
pre‐term birth or other birth‐related outcomes.
It is too soon to draw a final conclusion as to whether the so‐called ‘systemic link’ is of major public
health relevance, or not. Caution is warranted. The biological plausibility model of the systemic link
assumes that the larger the wound surface area, the greater the chances of bacteremia, and that the
large wound surface persists over substantial time periods. Are some of the model assumptions overly
optimistic? For example, the combined contact surface area between biofilms and pocket epithelium in
patients with generalized periodontitis was estimated as up to 70 cm2,297 potentially resulting in an
impressively large wound surface.290 However, the overwhelming majority of patients with chronic
periodontitis do not show signs of disease activity in all pockets simultaneously,364 and phases of such
activity are typically short‐term. Indeed, detection of active periodontal disease is a daunting task in
most patients because of its elusive character. The disease is often present at only a few sites, which
could mean that the effective wound size is considerably smaller than previously estimated, possibly just
a few square centimeters.173, 282 Although not impossible, detection of remote effects of such a small
wound is a formidable challenge.

Treatment modalities for gingivitis and periodontitis
Historical overview

Local mechanical debridement of the teeth and root surfaces has been advocated for centuries as a
treatment for diseases of the periodontium, with descriptions of calculus removal being found in the
ancient writings of almost all known civilizations. Various other therapies such as cauterization using
thermal or chemical agents, use of astringents on the soft and hard tissues, as well as soft‐tissue
removal using curettes or surgical blades have been advocated at various times and in various cultures
as treatments for periodontal diseases.127, 128 Scientific and technical progress in the 19th and 20th
centuries, including better understanding of the histopathology of the disease and its microbial etiology,
as well as the development of radiography, local anesthesia and analgesia, made diagnosis and
treatment of periodontal diseases more standardized although not truly cause‐related.
After the seminal work by Löe et al.,232 demonstrating the cause and effect relationship between
bacterial plaque/biofilms and gingival inflammation, the second half of the 20th century saw an
explosion of research on cause‐related therapy for gingivitis and the most common phenotypes of
periodontitis. These centered on mechanical and chemical methods to attack the microbial origins of
disease. Later observations of differential host susceptibility to disease162, 234 and the discovery of
molecular mechanisms of tissue destruction in the periodontium243 suggested anti‐inflammatory or host
modulation approaches as potential means to address periodontal syndromes.202 Today it is universally
agreed that effective periodontal therapy for plaque‐related disease requires elimination of
inflammation through re‐establishment of a biologically acceptable ‘clean’ root surface. Current
therapeutic approaches all aim to achieve that end with minimal removal of cementum. Antimicrobials
and host‐modulating agents may be used as adjuncts to this basic and arguably ancient mechanical
approach to therapy. How, when and why these approaches fit into therapy is discussed below in the
context of treatment sequence, with emphasis on the most common form of disease: chronic
periodontitis.

Systemic and acute phases of treatment

General guidelines for dental treatment planning have been published377 based on five treatment
phases: systemic, acute, cause‐related, surgical corrective and maintenance (Table 5). The systemic
treatment phase is concerned with prevention of treatment complications, particularly in subjects in
whom periodontitis is associated with systemic disease, as well as with protection against disease
transmission. Another goal of the systemic phase is to optimize treatment outcomes by addressing
important subject‐based risk factors, such as smoking163, 315 and diabetes.389, 416 Although the systemic
treatment phase is crucial in many periodontal disease phenotypes, the acute treatment phase is usually
only implemented for symptomatic forms of periodontal disease, such as necrotizing periodontal
diseases, abscesses of the periodontium, and sometimes in cases of periodontitis associated with
endodontic lesions. In acute situations, the systemic treatment phase may be abbreviated, but cannot
be ignored. For such situations, control of pain and infection is paramount. Basic treatment approaches
for some common acute periodontal conditions are outlined in Fig. 4. As the majority of gingivitis and
tissue‐destructive periodontal diseases are non‐painful, most of the treatment for these conditions
occurs in the context of overall restoration of oral health during the active treatment phases.
Table 5. Guidelines for sequencing the treatment for periodontal patients. Modified and reproduced
with permission from377
I: Systemic phase

A Consultation with patient’s physician
B Pre‐medication
C Stress/fear management
D Any necessary treatment considerations for systemic disease
II: Acute phase
A Emergency treatment for pain and infection
B Addressing the urgent chief complaint
III: Cause‐related phase
A Oral hygiene education, patient motivation and risk assessment
B Mutual goal‐setting for acceptable outcomes/endpoints of therapy
i: Implementation of strategies for risk reduction
C Excavation of deep carious lesions
i: Determine restorability
D Extraction of hopeless teeth along with non‐surgical periodontal debridement
E Removal of plaque retentive factors
F Necessary endodontic and occlusal therapy
G Post‐treatment re‐evaluation
i: Objective assessment of endpoints of therapy
IV: Surgical corrective phase
A Resective/regenerative and implant surgical procedures
B Post‐surgical re‐evaluation
i: Objective assessment of endpoints of therapy
C Definitive prosthodontic restoration
V: Maintenance phase
A Periodic professional supportive care
B Reinforcement of oral hygiene instruction and motivation
C Annual multi‐pronged periodontal stability and risk re‐assessment
D Comprehensive professional supra‐ and subgingival plaque removal

E Radiographic updates and therapeutic interventions (as needed)

Figure 4. Common treatment strategies for acute periodontal conditions. ANUG: acute, necrotizing,
ulcerative gingivitis. ANUP: acute, necrotizing, ulcerative periodontitis. PRN: as needed. BID: twice a day.

Active treatment and maintenance

Periodontal treatment is often divided into disease control, surgical and maintenance phases. While
variations in the therapeutic approach are necessary for different forms of periodontal disease, these
three phases are generally applicable to asymptomatic periodontitis patients. The disease control phase
has also been termed the ‘initial’ or ‘cause‐related’ phase of treatment because it is primarily focused on
elimination of pathogenic subgingival biofilms as well as removal of factors that promote biofilm
formation and subsequent destructive inflammation. An overview of common treatment strategies for
gingivitis is presented in Fig. 5. For plaque‐induced gingivitis, the treatment centers on professional and
personal plaque removal, with proper training in needs‐related oral hygiene measures being critical.
Antiseptics can also play a role in reducing plaque and gingivitis. For non‐plaque‐induced gingivitis, it is
important to identify the source of inflammation and reduce or eliminate it whenever possible. Common
treatment approaches for chronic and aggressive periodontitis, in which tissue destruction has occurred,
are outlined in Fig. 6. In each case, active treatment centers on disruption of the pathogenic biofilm by
non‐surgical mechanical debridement using antimicrobial and sometimes anti‐inflammatory adjuncts,
and, as with all biofilm‐mediated oral disease, patient‐specific instruction in daily plaque removal.

Figure 5. Common treatment strategies for gingivitis. BID: twice a day.

Figure 6. Comparison of active treatment strategies for chronic and aggressive periodontitis.
While traumatic occlusion is not an etiological factor for periodontal disease, it is considered to be a
potential disease modifier. It is often addressed during initial therapy.5 Management of other potential
disease modifiers, such as psychological stress, osteoporosis and poor dietary habits, is often advocated.
Such interventions can be beneficial. However, little research has been performed to clarify the effects
of these other potential risk indicators on disease susceptibility, and even less research has been
performed regarding intervention.155
Success in the cause‐related phase is achieved when disease progression is halted or significantly
reduced, as determined by measurements taken upon re‐evaluation (Table 6). Important clinical
benchmarks for assessment of treatment success include reduction in bleeding on probing and probing
depth, together with gains in clinical attachment levels and optimization of needs‐related plaque
control. There is insufficient evidence to support the utility of microbial diagnostics as a tool in the
management of chronic periodontitis, although microbial assessment may play a useful role in guiding

therapy for aggressive periodontitis and phenotypes of disease that are non‐responsive to conventional
therapy.237
Table 6. Prediction of periodontal stability defined as a change in clinical attachment level of 0 ± 1
mm and no change in radiological bone level
Predictor

Level

Decision criterion

Long‐term stability

Reference

Diabetes (HbA1c)

Patient

HbA1c ≥ 9% (poor control)

Unfavorable

388

Obesity (BMI)

Patient

BMI ≥ 30 kg/m2

Unfavorable

310

Smoking

Patient

Current smoker

Unfavorable

258, 316, 396

Oral hygiene (HI)

Full
mouth

HI>30% consistently

Unfavorable

41

Radiographs

Site

Crestal lamina dura consistently
present

Favorable

322

Site

Loss in crestal bone height

Unfavorable

322

Site

Bleeding on probing = 0
consistently

Favorable

185, 220

Site

Bleeding on probing > 0
consistently

Questionable

41, 76, 219

Full
mouth

Bleeding on probing > 30%
consistently

Unfavorable

185

Tooth

All tooth sites GI ≤ 1 consistently

Favorable

222

Tooth

All tooth sites 1 < GI ≤ 2
consistently

Questionable

222

Tooth

All tooth sites GI ≥ 2 consistently

Unfavorable

222

Bleeding on probing

Gingival inflammation
(GI)

Predictor

Probing depth (PD)

Level

Decision criterion

Long‐term stability

Reference

Site

Change in PD = 0 ± 1 mm

Favorable

41, 75, 76

Site

Change in PD ≥ 2 mm since
previous visit

Unfavorable

41, 75, 76

Site

Eight or more sites with PD ≥ 5
mm

Unfavorable

76, 258

Site

PD ≥ 6 mm

Unfavorable

258

For definitions of long‐term stability criteria, see.215
The surgical/corrective phase of therapy is performed only after thorough re‐evaluation of initial
therapy has suggested that residual infection/inflammation exists, and compliant patients are still at risk
for disease progression (Fig. 6). In the surgical phase of therapy, periodontal regeneration or resection
may be attempted, depending on the bone and soft‐tissue architecture. Useful treatment algorithms
have been published recently and will not be detailed here.190 A combination of resective and
regenerative procedures is often used at a single surgical site (Fig. 7). However, surgical therapy is best
avoided in patients whose plaque control is inadequate228, 287 or who are heavy smokers.316

Figure 7. Periodontal surgical intervention for severe chronic periodontitis that combines resective and
regenerative strategies to reduce pocket depth and achieve a healthy and maintainable periodontium.
(A) Chronic periodontal abscess showing exudate on palpation of teeth 24 and 25. (B) Probing confirms a
12 mm mucogingival/osseous defect. (C) Pre‐treatment periapical radiograph showing advanced bone
loss. (D) Surgical flap after defect and root debridement and prior to bone graft and Emdogain®. (E) The
tissues have been positioned apically and sutured. (F) Probing depths are stable and maintainable. (G)
Healthy but receded gingival tissues are seen five years after treatment. (H) Periapical radiograph
suggesting some improvement in bone level after 5 years.
The supportive or maintenance phase of therapy involves secondary prevention of periodontal disease.3
Ideally, this phase is entered only after all signs of disease have been eliminated or substantially reduced
and the long‐term stability of periodontal health is highly probable. A multi‐pronged approach to regular
reassessment of periodontal health during the supportive phase is critical to long‐term success in
preventing disease recurrence (Table 6).100 Although absence of bleeding on probing is a useful indicator
of health,220 increasing pocket depth over time, or pockets deeper than 6 mm coupled with consistent
bleeding on probing, are still the best predictors of disease progression.41, 75, 258 These measures have
been proven useful and are easy to record, and so have become important clinically.398 Recently,
Offenbacher et al.291, 292 proposed what they call the ‘biofilm–gingival interface classification’, based on
classic clinical disease markers coupled with microbial and host molecular markers for disease, to
describe different biological phenotypes of periodontitis. The molecular markers may turn out to be
useful adjuncts to the standard clinical markers of probing depth and bleeding on probing.

Efforts continue in the hope of developing saliva‐ or crevicular fluid‐based diagnostic systems that may
help to distinguish between health and disease based on microbial or host inflammatory markers.54 As
yet, no system is in wide use, perhaps due to the fact that detailed multi‐pronged clinical observations
continue to be very effective.

Non‐surgical cause‐related treatment
Plaque control

The first step in treatment of any form of periodontitis is training the patient in proper plaque removal.
Although effective oral hygiene provides limited but positive changes in signs of disease, such as
reductions in probing depths and bleeding on probing,39, 40, 67, 238 optimal daily plaque control is the most
important determinant for long‐term success in periodontal therapy.35, 38, 354 A systematic review on the
effects of a prophylaxis combined with a single episode of oral hygiene instruction emphasizing use of a
manual toothbrush demonstrated a small but consistent reduction in gingivitis, even though it was clear
that plaque reduction in these studies was not optimal.405 More focused training in needs‐related plaque
removal, such as flossing, the use of woodsticks or other interdental hygiene aids, can be extremely
effective in reducing disease long‐term when combined with regular professional mechanical
cleaning.33, 34, 38, 210 Combining interdental plaque removal with an already existing habit of
toothbrushing has been strongly advocated.37
Powered toothbrushes have been shown in systematic reviews to provide a modest additional short‐
term benefit over manual toothbrushing.330, 359 Compliance is an issue over the long‐term, and even the
best powered brushes have yet to demonstrate clinically relevant proximal plaque removal. It is clear
that repeated instruction and motivation on interdental cleaning by any means is necessary for long‐
term success, particularly in the high‐risk posterior teeth.369, 370 When interproximal soft tissue has
receded, use of interdental brushes is of particular value.72, 197, 409

Removing plaque‐retentive factors

The removal of plaque‐retentive factors as part of initial periodontal therapy is clearly important.
Multiple retrospective cross‐sectional studies as well as short‐term longitudinal studies have confirmed
the negative microbiological and clinical effects of subgingival and otherwise non‐ideal restoration
margins.294

Scaling and root planing

Mechanical root cleaning as a treatment for periodontitis has been advocated for centuries, and scaling
and root planing is still the ‘gold standard’ treatment for chronic periodontitis. This cause‐related
approach is aimed at removal of pathogenic biofilms, toxins and calculus, and re‐establishment of a
biologically acceptable root surface. Shrinkage of the periodontal pocket occurs as a combination of soft
tissue reattachment to the clean root surface and recession of the soft‐tissue margin as a result of a
decrease in the inflammatory infiltrate in the periodontal tissues.39, 40 Significant reductions in the levels
of motile rods and spirochetes are a common finding in areas that show clinical improvements after
treatment.142, 161, 327 Evidence for clinical improvement includes positive changes in tissue color, contour
and consistency, as well as in reductions of bleeding on probing and pocket depth, and gain in
attachment.
Badersten et al.40 proposed that, for non‐molar teeth, there is no true threshold pocket depth where
non‐surgical periodontal therapy becomes ineffective. However, others have suggested that the ability
to adequately remove biofilm and calculus to achieve a biologically acceptable root surface depends on
the depth of the pocket, the root anatomy, the instrumentation, the experience of the operator and the
approach used.57, 61, 62, 106, 116, 374 Systematic reviews have indicated that powered instruments, such as

magnetostrictive and piezoelectric ultrasonic scalers and sonic scalers, are at least as effective as
curettes in mechanical debridement, but the powered instruments tend to be more efficient.402, 414
There is some evidence that powered instruments may be more effective in areas that are difficult to
access, such as furcations and deeper pockets.50, 256 When used properly, the powered instruments
appear to remove less root structure.346

Adjunctive treatments during initial‐phase therapy
Systemic antibiotics

Use of systemic antibiotics as an adjunct to scaling and root planing has become the standard of care in
aggressive and non‐responsive forms of periodontitis. However, the decision to use a systemic antibiotic
must be made based on the patient’s medical and dental history. Performing microbial culture and
obtaining antibiotic sensitivity data are recommended.8
Systemic antimicrobials have also shown some benefit with regard to clinical attachment level gains in
short‐term treatment studies of chronic and aggressive periodontitis, with the benefit being more
pronounced in deeper sites.141, 142 However, as mechanical treatment alone is quite often effective, and
development of antibiotic‐resistant bacterial strains is a growing problem, widespread use of such
adjunctive therapy for chronic periodontitis cannot be justified.141, 411 Many systemic antimicrobials and
combinations of agents were tested in clinical trials, with tetracyclines, metronidazole and combinations
of metronidazole with amoxicillin being most frequently reported.141 Systemic use of antibiotics as an
adjunct to non‐surgical periodontal therapy may have at least a short‐term positive effect on systemic
levels of inflammation.352 and on glycemic control in diabetics.138

Local antimicrobial treatment

The delivery of high levels of antimicrobial directly to the disease site has advantages over systemic
antibiotics, including fewer side‐effects and non‐compliance issues. Several systems have been
approved by the Food and Drug Administration for use in the USA, and in other countries. By and large,
systems showing ease of use, consistent retention at the site of placement, and slow, steady release of
high concentrations of antimicrobial have become popular adjunctive therapies. Non‐setting gel
preparations have fared poorly, presumably due to unfavorable release characteristics.87, 392 Several
large randomized, multi‐center clinical trials have demonstrated modest short‐term clinical benefits of
antimicrobials as an adjunct to scaling and root planning.107, 109, 179, 419 Test agents with favorable
pharmacodynamics included tetracycline fibers, chlorhexidine chips, minocycline microspheres and
doxycycline gel. Their use in the initial stage of therapy has shown statistically significant improvements
in probing depth reduction, and clinical attachment level gains in some cases. However, reviews have
suggested that the magnitude of the changes is of questionable clinical relevance.52, 88, 133, 144 Moreover,
the cost/benefit ratio remains unproven.99, 158 Currently, the most accepted indication for local
antimicrobial treatment is in chronic periodontitis patients with isolated pockets of moderate disease
that have not responded to mechanical therapy alone (Fig. 6).11
Recent trials using locally delivered minocycline microspheres as part of ‘intensive periodontal therapy’
demonstrated short‐term alterations in several systemic inflammatory markers in addition to providing
local clinical benefits that lasted for several months.92, 399

Host modulation

The concept of modulating the inflammatory response as a way to reduce or prevent periodontal
breakdown has been investigated since Golub et al. observed that minocycline inhibited collagenase
activity in a germ‐free rat model.129 As periodontal bone and attachment loss are the result of
destructive inflammation, it stands to reason that a reduction of the host response should provide a

useful adjunct to typical mechanical and chemical antimicrobial approaches during disease control or
maintenance phases of treatment (Fig. 6). Host modulation approaches have been based primarily on
damping down effector molecules such as matrix metalloproteinases and prostanoids, although more
recent efforts to inhibit destructive inflammation have targeted upstream mediators, such as p38 MAPK
(203), as well as novel downstream lipid mediators, lipoxins and resolvins, that actually appear to
resolve the chronic inflammatory response rather than simply suppress it.148, 407, 408 An additional
approach, focused on alterations of bone metabolism by bisphosphonates, has also been studied.124
While studies of non‐steroidal anti‐inflammatory drugs, bisphosphonates, and most recently p38MAPK
inhibitors, lipoxins and resolvins, have shown proof of concept, only low‐dose doxycycline has obtained
US Food and Drug Administration approval for treatment of periodontal disease. In several large,
randomized multi‐center clinical trials, investigators demonstrated modest clinical benefits with
adjunctive low‐dose doxycycline after scaling and root planing in subjects with moderate to severe
generalized chronic periodontitis.64, 286, 317 In addition, a systematic review concluded that adjunctive use
of low‐dose doxycycline, together with non‐surgical scaling and root planing, provided a statistically
significant improvement over non‐surgical therapy alone.325 However, the clinical relevance of the
adjunctive benefits demonstrated for this therapy has been questioned.133 Moreover, compliance is
always an issue when patients are required to take frequent medication for prolonged periods of time,
and a modified version of low‐dose doxycycline (40 mg everyday) was introduced in response to such
issues.319 Controversy remains regarding the effect of low‐dose doxycycline in smokers.280, 318 From a
microbiological viewpoint, there is a growing body of evidence suggesting that the standard regimen
low‐dose doxycycline (20 mg twice a day) has no detrimental effects on the commensal flora of the
oral cavity or the gastrointestinal tract.391, 412, 413
However, caution remains regarding application of low‐dose doxycycline. Matrix metalloproteinases are
ubiquitous and necessary for normal physiological processes, and the potential consequences of long‐
term matrix metalloproteinase inhibition on other systems are not yet clear. Host modulation
therapeutic agents under development show promise, but a magic bullet isn’t on the horizon.202, 203, 408
Further advances in this area of therapy await better classification of diseases and identification of the
multi‐faceted molecular basis for the biofilm/host imbalances that produce destructive inflammation. A
glimpse into the future was provided by the observation that use of resolvins, but not aspirin‐triggered
lipoxins, have a positive effect on human neutrophils from subjects with localized aggressive
periodontitis, and that topical resolvins reverse periodontal inflammation in the rabbit periodontal
disease model.148 Scientists have expressed great hope in pharmacogenomics,121 in which the individual
genetic and epigenetic make‐up of the patient will guide efforts to modulate the host response via drugs
and even diet. DNA microarray analysis will be useful in this endeavor.209 Using these molecular
approaches, we may finally begin to develop individualized therapies with predictable outcomes for
various periodontal diseases.

Full‐mouth disinfection

The concept of same‐day full‐mouth ‘disinfection’ (antisepsis) was introduced in 1995320 as a potentially
more effective non‐surgical periodontal therapy than the conventional quadrant‐by‐quadrant scaling
approach. Many follow‐up studies have been performed, with varied results.25, 26, 205, 273 The idea of
radically reducing the levels of bacterial pathogens from all intra‐oral niches, including the gingival
crevice and periodontal pockets, is conceptually sound. However, variations in study designs have
prevented a clear answer as to whether the concept will effectively translate into a widely accepted
clinical approach. The pertinent evidence was assessed at the 6th European Workshop of
Periodontology. The reviewers concluded that full‐mouth scaling and root planing with or without
adjunctive antiseptics does not provide significant clinical benefit beyond conventional, staged

debridement. It was concluded that any of the three treatment approaches are valid ways to accomplish
debridement in the cause‐related treatment phase for chronic periodontitis.337

Lasers

The use of laser light to disinfect the periodontal pocket more efficiently has been another area of
intense research.22, 90, 393 A recent review of the available evidence80 concluded that results are
inconsistent, and that the radiation parameters and techniques have not been reported in enough detail
to make useful recommendations. According to Schwartz et al.,349 use of the Er‐YAG laser as a
monotherapy may be useful in the cause‐related phase of therapy, as it appears to provide similar
clinical outcomes to conventional mechanical debridement, but the evidence is weak. Other lasers such
as the CO2, Nd:YAG and Nd:YAP lasers have higher potential for thermal damage to the root surface, and
have not shown a clinical benefit, and as such are not recommended.337 The technology appears to
require more development and testing before it can be considered a substitute for classic mechanical
debridement.80
Photodynamic therapy is another technology of great potential.184 The essence of photodynamic
therapy is to load bacteria with a photoreactive dye, such as toluidine blue, and subsequently expose
the dye–bacteria complex to tissue‐penetrating light. The combination of dye and light energy leads to
formation of singlet oxygen reactive species that can cause cell death. Photodynamic therapy could be
an interesting adjunct to scaling and root planing, but this approach is still in development.23, 97

Surgical phase of treatment

When therapeutic targets are not achieved following appropriate cause‐related treatment, a surgical
approach may be indicated (Fig. 6). Several surgical procedures have been well documented as a means
to gain access to facilitate instrumentation of the root surfaces, reducing pocket depths and restoring
clinical attachment. These surgical approaches have been utilized in treatment of periodontal disease
for decades, and are broadly classified as access, resective or regenerative procedures. The pocket
depth and bone architecture will dictate which surgical approach is indicated.

Access treatment

There have been vigorous debates over the past century concerning the relative merits of surgical and
non‐surgical treatment for periodontitis.128 In the 1980s, several groups published longitudinal clinical
trials comparing scaling and root planing to various surgical procedures with or without osseous re‐
contouring. In general, the non‐surgical treatments compared reasonably well to more invasive
approaches when surrogate outcomes, such as change in probing depth and clinical attachment level,
were used.186-188, 228, 308, 321 Unfortunately, the vast majority of these trials used a split‐mouth design,
which has serious deficiences, including carry‐across effects.101, 170, 225 This design is no longer
recommended for comparative efficacy studies of periodontal treatments.
A more recent 12‐year, randomized, parallel‐group clinical trial compared scaling and root planing to
surgical access. It showed that surgical access resulted in fewer teeth being lost over time as well as
fewer subjects showing continued disease progression. This was particularly evident over the first three
years of the study.354 Over this period, approximately 80% of the subjects who received only scaling and
root planing reached a stable endpoint, while 20% continued to show signs of significant clinical
attachment loss. However, recognizing the 20% of patients who do not reach a stable endpoint after
non‐surgical therapy remains a formidable challenge for the clinician. In addition, the study only
assessed single‐rooted teeth,354 and did not consider the more difficult furcation areas in multi‐rooted
teeth.

Resective procedures

Resective procedures are designed to reduce or eliminate periodontal probing depths and establish
favorable gingival and osseous contours that will allow more efficient oral hygiene and periodontal
maintenance. Two soft tissue resective procedures that have been employed in periodontal treatment
for many years are gingivectomy and gingivoplasty.89, 105, 410 Both have been shown to be effective for
reducing probing depths and contouring enlarged gingival tissues. However, these surgical techniques
are limited to areas where only soft‐tissue contours need to be addressed. They are not indicated when
access to or modification of underlying bone contours is necessary.
As a result of the limitations of gingivectomy, use of mucogingival flaps became favored, and is more
conducive to gaining access, pocket reduction and elimination of osseous defects. Resective
mucogingival flaps described in the literature include apically positioned flaps with and without osseous
re‐contouring.119, 183, 288, 345 Studies have demonstrated that the effects of apically positioned flaps with
and without osseous resection are predictable in terms of pocket reduction and long‐term stability. In a
systematic review of randomized controlled trials comparing surgical to non‐surgical therapy, it was
observed that surgical therapy consistently provided greater pocket depth reduction and clinical
attachment gain at deeper sites (≥6 mm pocket depth) compared to non‐surgical therapy.154
Even back in the 1950s, it was a concern that deeper pockets might leave a nidus for re‐infection. This
was corroborated by more recent findings that periodontal pathogens such as P. gingivalis and
spirochetes are more prevalent in deeper pockets,198, 272 and subjects with a higher prevalence of deeper
pockets have a tendency to show greater disease progression over time.76, 258 Compared with non‐
surgical therapy, osseous resective and modified Widman surgical procedures result in a reduction of
probing depths and clinical attachment gains for periods from one to 12 years.48, 187, 354
When periodontal resective procedures are utilized in the treatment of Class II and III furcations, long‐
term success is uncertain. Treatment of furcated teeth is challenging. As a result, they are likely to lose
more attachment than non‐furcated teeth. Surgical techniques that have demonstrated long‐term
success in treatment of furcated teeth include root resection,143, 332 tooth hemisection and
tunneling;143, 156 however, root caries is a frequently seen reason for failure. With the increased use of
dental implants, these types of resective therapies are performed much less often.

Regenerative procedures

Regeneration, not repair, is the optimal treatment outcome for patients with significant bone and
clinical attachment loss. However, obtaining predictable regeneration is challenging. An early surgical
modality that resulted in periodontal regeneration was the use of bone grafts343 for treating periodontal
infra‐bony defects. Over the years, numerous grafting materials have been reported to have potential
for true regeneration, including autogenous intra‐oral and extra‐oral grafts333, 344 and allografts
(Fig. 7).159, 353 This property is due to their osteogenic, osteoinductive and osteoconductive properties.
However, alloplastic grafting materials such as tricalcium phosphate,55, 371 porous194-196 and non‐
porous425-427 hydroxyapatite, xenografts and composites have been shown to have limited regenerative
potential, and act mainly as a filler.9

Guided tissue regeneration and biological agents

The concept of selectively isolating the epithelium and gingival connective tissues by use of resorbable
and non‐resorbable barrier membranes56, 131, 132, 244, 312, 313, 372, 373 to allow re‐population of cells from the
periodontal ligament, cementum and bone259 has led to clinical techniques described as guided tissue
regeneration. The literature suggests that when treating two‐ or three‐wall osseous defects, as well as
Class II furcations, clinical results are achieved using guided tissue regeneration that are more
predictable and durable than simple access flap surgery.260 Systematic reviews have confirmed the

clinical benefits observed for bone grafting and/or guided tissue regeneration in both intra‐bony defects
and buccal Class II furcation involvements.277, 328 In addition, specific flap designs such as the modified
papilla preservation technique85 and the simplified papilla preservation technique in areas with narrow
inter‐dental papillae have improved regenerative results due to better flap adaptation, tension‐free
closure and wound stability post‐surgically.86, 394 For technically demanding multi‐tooth recession
defects, use of a coronally positioned flap via a tunneling procedure is widespread.21 As for any surgical
approach, intensive post‐operative care influences the outcomes of these regenerative procedures.
Recent advances in understanding of the wound healing effects of growth factors and biological
mediators,311 such as platelet‐derived growth factor‐BB, insulin‐like growth factor,123, 241, 242, 341 enamel
matrix derivative (e.g., Emdogain®),153, 350 and bone morphogenetic proteins on the periodontal tissues
have given promise to the possibility of obtaining enhanced and predictable periodontal regeneration.415
Studies utilizing growth factors and biological mediators have demonstrated significant improvement in
clinical attachment and periodontal regeneration.68, 112, 279
For confined (three‐wall) intra‐bony defects, there is robust evidence for the use of enamel matrix
derivative in promoting tissue regeneration.400 From animal studies, it appears that there is little benefit
of addition of bone grafting materials to enamel matrix derivative or use of a guided tissue regeneration
membrane in such three‐wall defects and class II furcation defects. However, as the number of bony
walls decreases, there is evidence of superior regeneration when a combination of membrane and graft
material is used to surgically repair the defect.351 Much more research must be performed to assess the
range of materials available and their most efficient and cost–effective application in various defect
architectures.
A systematic review of studies on root conditioning during surgical exposure suggested that such
treatment does not result in any significant improvement in periodontal regeneration, and provides
little clinical advantage other than removal of a smear layer.252

Mucogingival procedures

A significant current focus is on improving oral–facial esthetics, creating an emphasis on mucogingival
surgery to enhance the periodontal gingival complex. A more appropriate and contemporary term for
such surgery is periodontal plastic surgery. Periodontal plastic surgery is designed to correct the
dimensions and amount of gingival tissue in the esthetic zone, provide root coverage lost due to soft‐
tissue recession, preserve the bone height of an extraction socket, and perform ridge augmentation. A
detailed history of these procedures is beyond the scope of this review, and readers are referred to a
review on the development of periodontal plastic surgery.269

Supportive phase of treatment

Following completion of active periodontal therapy, it is essential that a periodontal maintenance
schedule be established. Studies have shown that tooth loss in periodontal patients is related to the
frequency and quality of their maintenance care.38, 420 In addition, periodontal surgical therapy may fail
in patients who are seen at infrequent maintenance intervals.103, 287 A recent systematic review
confirmed that patients who are seen at regular intervals for supportive periodontal therapy experience
less attachment loss and lose fewer teeth.122 Therefore, it is very important for each periodontal patient
to receive comprehensive periodontal maintenance treatment at appropriate intervals after active
periodontal therapy as outlined in Table 5 and Fig. 6. The periodontal disease status should be evaluated
and communicated to the patient using the same multi‐pronged approach to re‐assessment as used
after active treatment (Table 6). Intervals between periodontal maintenance visits should range from 2–

6 months depending on the patient’s disease phenotype and history, among other things. Shorter
intervals decrease the likelihood of progression of the disease.81

Concluding remarks

Periodontal diseases are arguably among the most ancient and common infectious diseases affecting
humans, leading to permanent destruction of the supporting structures of the dentition and ultimately
tooth loss. It has been established that dental biofilm (“plaque”), consisting of many microbial species
and their products, is an etiological agent of periodontal disease. It is widely accepted that
immunological and inflammatory responses to dental plaque via host‐parasite interaction are
manifested by clinical signs and symptoms of periodontal diseases. The outcome of this interaction can
be modulated by other components known as risk factors (modifiers), either inherent (genetic) or
acquired (environmental) in nature, significantly affecting the initiation and progression of periodontal
diseases of different types. While definitive genetic factors responsible for either susceptibility or
resistance to periodontal diseases await definitive identification and verification, a small number of
environmental factors affecting the pathogenesis of periodontal diseases have been described. They
include, among others, smoking, diabetes, medication, and nutrition.
Currently, periodontal diseases are classified based upon clinically observed disease traits using
radiographs and clinical examination: gingivitis; chronic periodontitis; aggressive periodontitis;
periodontitis as manifestation of systemic diseases; necrotizing ulcerative periodontitis; abscesses of the
periodontium; periodontitis associated with endodontic lesions; and developmental or acquired
deformities and conditions. Advances in genomics, molecular science, and personalized medicine may
result in guidelines for unambiguous disease definition and diagnosis in the future (Fig. 8). Recent
studies have implied that periodontal diseases and several systemic conditions, such as diabetes,
cardiovascular disease, and pre‐term delivery are interconnected, although concrete relationships still
await to be ascertained. Therefore, by answering critical questions about the physiology of host‐parasite
interactions in periodontal diseases, scientists may be able to generate new information regarding the
pathogenesis of systemic medical disorders, and vice versa.

Figure 8. Example of a case of periodontal disease that is not captured by the current classification
system. (Top) Intra‐oral photographs of a 52‐year‐old Caucasian male who presented with a low plaque
index (10%), low full‐mouth bleeding on probing index (<5%), and a lifelong history of hard‐bristle
toothbrush use. There was no history of scaling and root planing or surgical debridement, and only
recent free soft‐tissue grafts on teeth 22 and 27 for recession coverage. The overly aggressive hygiene
probably accounted for some recession and abrasion. (Bottom) Significant generalized horizontal bone
loss is seen in the radiographs. Its etiology is unknown. This may represent a non‐inflammatory
destructive periodontal disease phenotype300 modified by traumatic toothbrush abrasion.
The therapeutic efforts for controlling periodontal diseases focus on the removal of dental biofilm from
the affected lesion, as active treatment centers on non‐surgical mechanical debridement with
antimicrobial and sometimes anti‐inflammatory adjuncts. The surgical therapy aims at gaining access to
the lesion and correcting unfavorable gingival/osseous contours to achieve a periodontal architecture
that will provide for more efficient oral hygiene and periodontal maintenance. In addition, recent
advances in tissue engineering have provided an efficient means to regenerate/repair periodontal
defects, based upon principles of guided tissue regeneration and utilization of growth factors/biologic
mediators. To maintain periodontal stability, these therapies must be supplemented by a long‐term
maintenance program (supportive periodontal therapy).
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